Adalimumab in Patients with Active Noninfectious Uveitis

2016642 citationsJournal Articlebronze Open Access

Authors

Glenn J. Jaffe · The University of Texas Health Science Center at San Antonio

Andrew D. Dick · University College London

Antoine P. Brézin · Hôpital Cochin

Quan Dong Nguyen · The University of Texas Health Science Center at San Antonio

Jennifer E. Thorne · University College London

Philippe Kestelyn · The University of Texas Health Science Center at San Antonio

Talin Barisani‐Asenbauer

Abstract

In our trial, adalimumab was found to be associated with a lower risk of uveitic flare or visual impairment and with more adverse events and serious adverse events than was placebo. (Funded by AbbVie; VISUAL I ClinicalTrials.gov number, NCT01138657 .).

Topics & Keywords

Ocular Diseases and Behçet’s Syndrome Systemic Lupus Erythematosus Research Vasculitis and related conditions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 375, Issue 10, pp. 932-943

DOI: 10.1056/nejmoa1509852

Field-Weighted Citation Impact: 53.87